×
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
NASDAQ:MITO

Stealth BioTherapeutics Stock Forecast, Price & News

$0.28
-0.01 (-3.46%)
(As of 06/24/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.28
$0.30
50-Day Range
$0.18
$0.49
52-Week Range
$0.16
$1.62
Volume
212,067 shs
Average Volume
1.88 million shs
Market Capitalization
$16.73 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.25
30 days | 90 days | 365 days | Advanced Chart

Receive MITO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Stealth BioTherapeutics and its competitors with MarketBeat's FREE daily newsletter.

MITO Stock Forecast (MarketRank)

Overall MarketRank

1.68 out of 5 stars

Medical Sector

916th out of 1,411 stocks

Pharmaceutical Preparations Industry

458th out of 672 stocks

Analyst Opinion: 3.5Community Rank: 4.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
Stealth BioTherapeutics logo

About Stealth BioTherapeutics (NASDAQ:MITO)

Stealth BioTherapeutics Corp, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. Its lead product candidate is Elamipretide that is in phase 3 clinical trial to treat barth syndrome, phase 2/3 clinical trial for the treatment of duchenne cardiomyopathy, phase 2a clinical trial to treat friedreich's ataxia, phase 2 clinical trial for the treatment of dry age-related macular degeneration, phase 2 clinical trial to treat leber's hereditary optic neuropathy, and phase 3 clinical trial for the treatment of replisome myopathies. The company's product candidates also include SBT-20 to treat complications of diabetes, renal diseases, ocular diseases, neurodegenerative, Parkinson's, Alzheimer's, Huntington's, and ALS diseases; SBT-550 for rare neurological indications; and SBT-272, a peptidomimetic that targets the mitochondria and stabilizing mitochondrial function under conditions of oxidative stress, as well as SBT 550. Stealth BioTherapeutics Corp was incorporated in 2006 and is based in George Town, the Cayman Islands.

MITO Stock News Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:MITO
Fax
N/A
Employees
29
Year Founded
N/A

Company Calendar

Last Earnings
5/18/2022
Today
6/26/2022
Next Earnings (Estimated)
8/04/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$2.25
High Stock Price Forecast
$3.00
Low Stock Price Forecast
$1.50
Forecasted Upside/Downside
+706.5%
Consensus Rating
Buy
Rating Score (0-4)
3
Research Coverage
2 Analysts

Profitability

Net Income
$-52.53 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$21.09 million
Book Value
($0.79) per share

Miscellaneous

Free Float
N/A
Market Cap
$16.73 million
Optionable
Not Optionable
Beta
2.09














Stealth BioTherapeutics Frequently Asked Questions

Should I buy or sell Stealth BioTherapeutics stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Stealth BioTherapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Stealth BioTherapeutics stock.
View analyst ratings for Stealth BioTherapeutics
or view top-rated stocks.

What is Stealth BioTherapeutics' stock price forecast for 2022?

2 Wall Street research analysts have issued 1 year price targets for Stealth BioTherapeutics' shares. Their MITO stock forecasts range from $1.50 to $3.00. On average, they anticipate Stealth BioTherapeutics' share price to reach $2.25 in the next year. This suggests a possible upside of 706.5% from the stock's current price.
View analysts' price targets for Stealth BioTherapeutics
or view top-rated stocks among Wall Street analysts.

How has Stealth BioTherapeutics' stock price performed in 2022?

Stealth BioTherapeutics' stock was trading at $0.83 at the start of the year. Since then, MITO shares have decreased by 66.4% and is now trading at $0.2790.
View the best growth stocks for 2022 here
.

Are investors shorting Stealth BioTherapeutics?

Stealth BioTherapeutics saw a increase in short interest during the month of May. As of May 31st, there was short interest totaling 1,480,000 shares, an increase of 95.4% from the May 15th total of 757,400 shares. Based on an average daily volume of 2,470,000 shares, the short-interest ratio is currently 0.6 days.
View Stealth BioTherapeutics' Short Interest
.

When is Stealth BioTherapeutics' next earnings date?

Stealth BioTherapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Stealth BioTherapeutics
.

How were Stealth BioTherapeutics' earnings last quarter?

Stealth BioTherapeutics Corp (NASDAQ:MITO) issued its quarterly earnings results on Wednesday, May, 18th. The company reported ($0.12) EPS for the quarter, missing analysts' consensus estimates of ($0.02) by $0.10.
View Stealth BioTherapeutics' earnings history
.

Who are Stealth BioTherapeutics' key executives?

Stealth BioTherapeutics' management team includes the following people:
  • Ms. Irene P. McCarthy J.D., Pres ,CEO, Sec. & Director (Age 57)
  • Mr. Henry Hess, Chief Legal Counsel
  • Dr. Ben R. Bronstein M.D., Chief Medical Officer (Age 72)
  • Mr. Brian Hotchkiss, VP of Bus. Devel. & Strategy

What other stocks do shareholders of Stealth BioTherapeutics own?

When did Stealth BioTherapeutics IPO?

(MITO) raised $81 million in an initial public offering (IPO) on Friday, February 15th 2019. The company issued 6,200,000 shares at a price of $12.00-$14.00 per share. Jefferies, Evercore ISI and BMO Capital Markets served as the underwriters for the IPO and Nomura was co-manager.

What is Stealth BioTherapeutics' stock symbol?

Stealth BioTherapeutics trades on the NASDAQ under the ticker symbol "MITO."

How do I buy shares of Stealth BioTherapeutics?

Shares of MITO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Stealth BioTherapeutics' stock price today?

One share of MITO stock can currently be purchased for approximately $0.28.

How much money does Stealth BioTherapeutics make?

Stealth BioTherapeutics (NASDAQ:MITO) has a market capitalization of $16.73 million and generates $21.09 million in revenue each year. The company earns $-52.53 million in net income (profit) each year or ($0.52) on an earnings per share basis.

How many employees does Stealth BioTherapeutics have?

Stealth BioTherapeutics employs 29 workers across the globe.

How can I contact Stealth BioTherapeutics?

Stealth BioTherapeutics' mailing address is 275 GROVE STREET SUITE 3-107, NEWTON MA, 02466. The official website for Stealth BioTherapeutics is www.stealthbt.com. The company can be reached via phone at 617-600-6888 or via email at [email protected].

This page (NASDAQ:MITO) was last updated on 6/26/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.